Trump resists calls for tougher restrictions on China tech; ByteDance expands AI hires in the US; India’s AI summit had little China; Xiaomi doubles down on indigenous efforts.
Today in Gavekal Technologies Briefing we assess the growing fear in the US that its biotech industry is about to be overwhelmed by a flood of low-cost Chinese competition. The fear is overblown: the American edge in underlying innovation is solid, and US and European big pharma will reap most of the financial gains from the new drugs starting to come out of China. But to maintain its lead into the 2030s and beyond, the US biomedicine industry needs some serious regulatory reform.